The role of luteal support during IVF: a qualitative systematic review

Autor:	Miro Kasum, Vlatka Tomic, Katarina Vucic
Rok vydání:	2019
Předmět:	Adult Infertility medicine.medical_specialty Pregnancy Rate Endocrinology Diabetes and Metabolism Qualitative evidence medicine.medical_treatment media_common.quotation_subject 030209 endocrinology & metabolism Fertility Fertilization in Vitro Luteal Phase IVF/ICSI cycles Progesterone infertility luteal phase support ovarian stimulation 03 medical and health sciences 0302 clinical medicine Endocrinology Pregnancy medicine Humans Birth Rate reproductive and urinary physiology Luteal support media_common 030219 obstetrics & reproductive medicine In vitro fertilisation urogenital system Obstetrics business.industry Pregnancy Outcome Obstetrics and Gynecology medicine.disease Female Progestins business hormones hormone substitutes and hormone antagonists
Zdroj:	Gynecological Endocrinology. 35:829-834
ISSN:	1473-0766 0951-3590
DOI:	10.1080/09513590.2019.1603288
Popis:	The aim of this review is to provide qualitative evidence-based synthesis regarding efficacy of luteal-phase support on fertility outcome in women undergoing in vitro fertilization (IVF) with respect to clinical or live birth rates and pregnancy loss rates. Although the need of luteal phase support in IVF/ICSI cycles is well- known, the optimal start, dosage, route and the duration of the luteal phase support is still subject of debate. Data suggest that the optimal period to start with the luteal phase support would be between 24–72 hours after oocyte- retrieval and should continue at least until a positive pregnancy test is achieved. However, the majority of IVF-centers worldwide provide progesterone support up to 8 weeks of pregnancy. Among the well-established routes of luteal support, oral dydrogesterone and subcutaneous progesterone represent new and interesting routes of progesterone administration. The current studies support these routes of progesterone administration use in terms of comparable pregnancy rates and pregnancy loss rates to vaginal and intramuscular progesterone. Furthermore, the acceptance and tolerability among patients seems to be even better. In the frozen-thawed embryo transfer, dydrogesterone and vaginal progesterone are not effective as monotherapy treatments ; however, when combined there is no reason to avoid one or the other in this setting.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d9919a650eb18070c69fd192abef0e https://doi.org/10.1080/09513590.2019.1603288 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.